Camelia sells RPRX 16.76: Repros Therapeutics Downgraded to Neutral at Piper Jaffray (RPRX)
Repros Therapeutics (NASDAQ:RPRX) was downgraded by research analysts at Piper Jaffray from an âoverweightâ rating to a âneutralâ rating in a report released on Wednesday, TheFlyOnTheWall.com reports. They currently have a $24.00 price objective on ... ...
16 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home